The chief of surgical oncology at the UK Markey Cancer Center discussed liquid biopsies and their potential importance for diagnosing gastric cancer.
Joseph Kim, MD, chief of the division of surgical oncology at the UK Markey Cancer Center, spoke about the importance of liquid biopsies, specifically in gastric cancer, at the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California.
Transcription:
Currently, liquid biopsies are really in their infancy in diagnostics for (gastrointestinal) cancers, especially gastric cancer. Liquid biopsies are being tested in a number of cancers, but I think it’s particularly important for gastric cancer where it may be difficult to get enough tissue to do all of the genetic testing that we need, and so the liquid biopsies provide an avenue for us to get that data which would potentially help change the type of treatments that are offered for patients with gastric cancer.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.